• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对轻度和中度 COVID-19 的顺势疗法治疗方法:回顾性图表分析。

A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review.

机构信息

National University of Natural Medicine, Helfgott Research Institute, 2220 SW 1st Ave, Portland, OR, United States.

Canby Clinic, 452 NW 1st Ave, Canby, OR, United States.

出版信息

Complement Ther Med. 2021 Dec;63:102788. doi: 10.1016/j.ctim.2021.102788. Epub 2021 Nov 6.

DOI:10.1016/j.ctim.2021.102788
PMID:34748955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8570825/
Abstract

OBJECTIVES

The coronavirus disease 2019 (COVID-19) pandemic has led to significant morbidity and mortality. Although COVID-19 vaccination is available, therapeutic options are still needed. The goal of the present manuscript is to report on a treatment strategy used in a naturopathic medical practice for mild and moderate COVID-19.

DESIGN

A retrospective chart review was conducted of 30 consecutive patients diagnosed with mild and moderate COVID-19 who were provided multi-nutrient, herbal, and probiotic treatment in a rural, out-patient, naturopathic primary care setting.

MAIN OUTCOMES MEASURES

The primary outcome was treatment safety; secondary outcomes included changes in symptoms, progression to severe COVID-19, incidence of long COVID, and recovery time.

RESULTS

No side effects or adverse events were reported from treatment and all patients experienced resolution of symptoms presumed to be associated with COVID-19 infection. One patient who had been ill for 28 days prior to presentation was hospitalized. Five patients had an illness duration of more than one month. Time to treatment was correlated with duration of illness post-treatment (r = 0.63, p < 0.001) and more symptoms at presentation was correlated with a longer duration of illness (r = 0.52, p < 0.01).

CONCLUSIONS

In this retrospective chart review, a multi-nutrient, herbal, and probiotic therapeutic approach for mild and moderate COVID-19 appeared to be well-tolerated. Delay in seeking treatment after symptom onset, as well as more symptoms at presentation, were correlated with a longer duration of illness. This treatment strategy may have clinical benefit, warranting prospective clinical trials with confirmed COVID-19 cases.

摘要

目的

2019 年冠状病毒病(COVID-19)大流行导致了大量的发病率和死亡率。尽管有 COVID-19 疫苗,但仍需要治疗方法。本手稿的目的是报告一种在自然疗法医疗实践中用于轻度和中度 COVID-19 的治疗策略。

设计

对 30 例连续诊断为轻度和中度 COVID-19 的患者进行了回顾性图表审查,这些患者在农村门诊自然疗法初级保健环境中接受了多种营养素、草药和益生菌治疗。

主要结果测量

主要结果是治疗安全性;次要结果包括症状变化、进展为严重 COVID-19、长 COVID 的发生率和恢复时间。

结果

治疗无副作用或不良反应,所有患者均经历了与 COVID-19 感染相关的症状缓解。一名在就诊前已患病 28 天的患者住院。5 名患者的病程超过一个月。治疗时间与治疗后疾病持续时间呈正相关(r=0.63,p<0.001),就诊时症状越多与疾病持续时间越长呈正相关(r=0.52,p<0.01)。

结论

在这项回顾性图表审查中,一种用于轻度和中度 COVID-19 的多种营养素、草药和益生菌治疗方法似乎耐受性良好。症状出现后寻求治疗的时间延迟以及就诊时的更多症状与疾病持续时间延长有关。这种治疗策略可能具有临床益处,值得对确诊的 COVID-19 病例进行前瞻性临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fff3/8570825/2b7404dea26a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fff3/8570825/2b7404dea26a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fff3/8570825/2b7404dea26a/gr1_lrg.jpg

相似文献

1
A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review.针对轻度和中度 COVID-19 的顺势疗法治疗方法:回顾性图表分析。
Complement Ther Med. 2021 Dec;63:102788. doi: 10.1016/j.ctim.2021.102788. Epub 2021 Nov 6.
2
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
3
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
4
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
5
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.一项由日本综合传染病管理(IMJEDI 研究-RCT)开展的多中心、随机对照临床试验,评估了汉方药加味抗感煎剂(kakkonto with shosaikotokakikyosekko)在缓解 COVID-19 轻症和中度患者症状和预防重症方面的作用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9.
6
Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection.新冠感染后 6 个月持续的 COVID-19 症状和接种疫苗在 SARS-CoV-2 感染前后的作用。
JAMA Netw Open. 2023 Jan 3;6(1):e2251360. doi: 10.1001/jamanetworkopen.2022.51360.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
10
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.双盲、随机、对照临床试验评估同种异体间充质基质细胞治疗 COVID-19 所致急性呼吸窘迫综合征患者的疗效(COVID-AT):一项随机对照试验的研究方案的结构总结。
Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1.

引用本文的文献

1
Editorial: Multisystem inflammatory syndrome observed post-COVID-19: the role of natural products, medicinal plants and nutrients and the use of prediction tools supporting traditional forms of diagnosis.社论:COVID-19后观察到的多系统炎症综合征:天然产物、药用植物和营养素的作用以及支持传统诊断形式的预测工具的使用
Front Pharmacol. 2025 Jan 27;16:1539793. doi: 10.3389/fphar.2025.1539793. eCollection 2025.
2
Nutraceuticals and COVID-19: A mechanistic approach toward attenuating the disease complications.营养保健品与 COVID-19:减轻疾病并发症的一种机制方法。
J Food Biochem. 2022 Dec;46(12):e14445. doi: 10.1111/jfbc.14445. Epub 2022 Oct 14.
3

本文引用的文献

1
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.接受高效疾病修正治疗的多发性硬化症患者对新冠病毒mRNA疫苗的体液免疫反应
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021.
2
Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments.长新冠或新冠后综合征:推测的病理生理学、危险因素和治疗方法。
Infect Dis (Lond). 2021 Oct;53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22.
3
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
When Eastern Meets Western Medicine to Manage SARS-CoV-2/COVID-19 Patient: a Case Report.
中西医结合治疗新型冠状病毒肺炎患者一例报告
SN Compr Clin Med. 2022;4(1):58. doi: 10.1007/s42399-022-01142-z. Epub 2022 Feb 14.
实体器官移植受者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗系列的抗体反应。
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
4
Single-cell multi-omics analysis of the immune response in COVID-19.单细胞多组学分析 COVID-19 中的免疫反应。
Nat Med. 2021 May;27(5):904-916. doi: 10.1038/s41591-021-01329-2. Epub 2021 Apr 20.
5
Post-acute COVID-19 syndrome.新冠病毒感染后长期综合征。
Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
6
New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.抗击新冠病毒的新挑战:病毒变种、潜在疫苗及抗病毒药物的研发
Biosci Trends. 2021 May 11;15(2):126-128. doi: 10.5582/bst.2021.01092. Epub 2021 Mar 19.
7
The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report.基于瑜伽和阿育吠陀的整合疗法在 COVID-19/SARS-CoV-2 合并多种合并症高危病例治疗中的应用:病例报告。
J Med Case Rep. 2021 Feb 24;15(1):95. doi: 10.1186/s13256-020-02624-1.
8
TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.太普尤维德营养补充剂有助于快速治愈新冠病毒感染,并使鼻咽拭子PCR快速转阴:以便更好地对新冠疫情进行公共预防和治疗。
Am J Blood Res. 2020 Dec 15;10(6):397-406. eCollection 2020.
9
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.皮肤科接受免疫治疗患者的 SARS-CoV-2 疫苗接种的循证指南。
J Am Acad Dermatol. 2021 Jun;84(6):1652-1666. doi: 10.1016/j.jaad.2021.01.047. Epub 2021 Jan 19.
10
Immune determinants of COVID-19 disease presentation and severity.COVID-19 疾病表现和严重程度的免疫决定因素。
Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.